Ruiz-Nez B, Pruimboom L, Dijck-Brouwer DAJ, Muskiet FAJ
Building on this success, an expanding therapeutic pipelineincluding dual and triple agonists, amylin analogues, and other multimodal agentstargets complementary pathways and more closely aligns treatment with the biological complexity of obesity
Therefore, current treatment guidelines recommend maintenance of an optimal weight and stringent management of lipid levels in addition to glycemic control [3]
Additionally, Mounjaro , one of the newer diabetes drugs, which was approved in May 2022 and has a unique dual mechanism of action (it activates the GLP-1 hormone as well as another hormone called the glucose-dependent insulinotropic polypeptide or GIP, both helping to improve blood sugar) may be even more effective than semaglutide in reducing weight